Early Placebo Improvement May Be a Marker for Long-Term Placebo Response in Schizophrenia Trials
Investigators examine patients who demonstrated improvement after placebo injections and aimed to determine criteria to predict subsequent response.
Schizophrenia
Improving Care for T2D in Patients With Severe Mental Illness: Expert Q&A
Despite the clear need for improved management of T2D in patients with SMI, there is scant evidence regarding effective treatment strategies for this group.
FDA: Important Updates to the Clozapine REMS Program
Products covered under the Clozapine REMS program include Clozaril (HLS Therapeutics), Fazaclo (Jazz), and Versacloz (TruPharma), in addition to all generic versions.
Schizophrenia Risk Alleles, Peer Victimization Associated With Emotional Problems in Youth
Peer victimization may be an important modifiable factor in improving the developmental course among children.
Interaction Observed Between Age, Treatment Outcomes for Long-Acting Injectable Antipsychotic Medications
Researchers investigated subgroup responses to long-acting injectable medications haloperidol decanoate and paliperidone palmitate.
Social Anxiety in Schizophrenia: An Overlooked Problem
Emerging evidence has begun to elucidate the prevalence and outcomes associated with social anxiety disorder in schizophrenia.
Challenging Stigma: Should Psychiatrists Disclose Their Own Mental Illness?
Psychologists and psychiatrists discuss the stigma of mental health disorders in practicing clinicians.
Immune Variations Appear to Be Unrelated to Psychosis, Schizophrenia
Examination of raw data does not show a multi-modal distribution of immune parameter data in patients.
Schizophrenia Add-Ons: Beware the Flawed Meta-Analyses Touting Improvements
Clinicians should be discerning when evaluating meta-analyses of schizophrenia add-on therapies such as statins and antidepressants.
Aberrant Epstein-Barr Virus Response Associated With Schizophrenia
Investigators confirmed that people with schizophrenia have higher levels of antibodies to some but not all Epstein-Barr virus proteins, which indicates an aberrant response to Epstein-Barr virus infection that may be a factor in the immunopathology of schizophrenia and related disorders.
Next post in Schizophrenia and Psychoses
